FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Articles|November 30, 2021
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of November 30, 2021
Author(s)Sydney Jennings
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Advertisement
How many fully vaccinated Americans have received a booster dose?
According to the
How many people in the US have been vaccinated against COVID-19?
According to the CDC as of today, November 12, 2021, at 3:25 PM, EDT:
• 70.2% of total US population has received at least 1 dose
• 59.4% of total US population is fully vaccinated
• 59.4% of total US population is fully vaccinated
The 5 states/territories with the highest percentage of population fully vaccinated are:
1. Puerto Rico: 74.1%
2. Vermont: 72.9%
3. Rhode Island:72.6%
4. Maine: 72.3%
5. Connecticut: 72%
2. Vermont: 72.9%
3. Rhode Island:72.6%
4. Maine: 72.3%
5. Connecticut: 72%
How many cases of COVID-19 have been confirmed in the US?
According to the Johns Hopkins COVID-19 interactive map , as of today, November 30, 2021 at 4:23 PM, EDT, there have been:
• 48 520 789 confirmed cases and
• 779 802 deaths
• 779 802 deaths
The 5 states with the highest total confirmed cases are:
1. California: 5 082 595
2. Texas: 4 334 405
3. Florida: 3 721 503
4. New York: 2 724 160
5. Illinois: 1 809 875
2. Texas: 4 334 405
3. Florida: 3 721 503
4. New York: 2 724 160
5. Illinois: 1 809 875
Deaths: California has the highest number of deaths due to COVID-19 with 74 437 reported fatalities, followed by Texas with 73 826 and Florida with 61 538.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 262 666 501 confirmed cases, 5 213 740 deaths, and 7 989 250 512 vaccine doses administered.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.
TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.
In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.
Capsule-sponge DNA methylation test boosts Barrett’s screening access, showing high accuracy, strong tolerability, and promise for primary care triage to endoscopy.
ACOG's new guideline covers hormone therapy timing, neurokinin receptor antagonists, SSRIs/SNRIs, and nonpharmacologic options for menopause symptoms.
Advertisement
Advertisement
Trending on Patient Care Online
1
ACOG Issues Expanded Guideline on Managing Menopause-Related Vasomotor, Sleep, and Mood Symptoms
2
AI-Enhanced Virtual Reality Program Delivering CBT Shows Early Feasibility for Menopause Symptoms: TMS 2026
3
Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A
4
Elinzanetant Linked to Broad Improvements in Sleep Disturbance in Women With Moderate-to-Severe Vasomotor Symptoms
5